Travere Therapeutics Inc (TVTX)

09:20 AM

Travere Therapeutics price target raised to $30 from $24 at TD Cowen - Yahoo Finance

09:20 AM

08:10 AM

Travere Therapeutics, Inc. (NASDAQ:TVTX) Q4 2024 Earnings Call Transcript - Insider Monkey

08:10 AM

07:29 AM

Travere Therapeutics Full Year 2024 Earnings: EPS Misses Expectations - Yahoo Finance

07:29 AM

Feb 21, 2025

Travere Therapeutics’ Earnings Call Reveals Growth and Challenges - TipRanks

Feb 21, 2025

Feb 21, 2025

US FDA approves Mirum Pharma's genetic disorder drug -February 21, 2025 at 12:07 pm EST - Marketscreener.com

Feb 21, 2025

Feb 21, 2025

Travere Therapeutics, Inc. SEC 10-K Report - TradingView

Feb 21, 2025

Feb 21, 2025

Travere therapeutics chief medical officer sells $60k in stock - MSN

Feb 21, 2025

Feb 21, 2025

Travere Therapeutics Inc (TVTX) Q4 2024 Earnings Call Highlights: Strong Phil Spari Sales and ... - Yahoo Finance

Feb 21, 2025

Feb 20, 2025

Travere Therapeutics Posts Strong 2024 Financial Results - TipRanks

Feb 20, 2025

Feb 20, 2025

Earnings call transcript: Travere Therapeutics Q4 2024 sees earnings beat but stock drops - Investing.com

Feb 20, 2025

Feb 20, 2025

Compared to Estimates, Travere (TVTX) Q4 Earnings: A Look at Key Metrics - Yahoo Finance

Feb 20, 2025

Feb 20, 2025

Travere Therapeutics (TVTX) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance

Feb 20, 2025

Feb 20, 2025

Travere: Q4 Earnings Snapshot - Danbury News Times

Feb 20, 2025

Feb 20, 2025

Travere: Q4 Earnings Snapshot -February 20, 2025 at 04:27 pm EST - Marketscreener.com

Feb 20, 2025

Feb 20, 2025

Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times

Feb 20, 2025

Feb 20, 2025

Earnings: Travere Q4 Revenue Surges 84% as FILSPARI Sales Hit $132M in First Year | TVTX Stock News - StockTitan

Feb 20, 2025

Feb 20, 2025

What To Expect From Travere Therapeutics Inc (TVTX) Q4 2024 Earnings - Yahoo Finance

Feb 20, 2025

Feb 18, 2025

Travere Therapeutics (TVTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release - MSN

Feb 18, 2025

Feb 18, 2025

Entropy Technologies LP Makes New $214,000 Investment in Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat

Feb 18, 2025

Feb 18, 2025

Travere Therapeutics, Inc. (NASDAQ:TVTX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat

Feb 18, 2025

Feb 17, 2025

TVTX Stock Soars to 52-Week High, Reaching $20.36 - MSN

Feb 17, 2025

Feb 17, 2025

Curious about Travere (TVTX) Q4 Performance? Explore Wall Street Estimates for Key Metrics - Yahoo Finance

Feb 17, 2025

Feb 17, 2025

Travere Therapeutics (TVTX) Projected to Post Earnings on Thursday - MarketBeat

Feb 17, 2025

Feb 17, 2025

Leerink Partnrs Has Strong Forecast for TVTX FY2026 Earnings - MarketBeat

Feb 17, 2025

Feb 16, 2025

Travere Therapeutics (NASDAQ:TVTX) Given New $45.00 Price Target at Evercore ISI - MarketBeat

Feb 16, 2025

Feb 16, 2025

Travere Therapeutics, Inc. (NASDAQ:TVTX) Insider Peter Heerma Sells 3,074 Shares - MarketBeat

Feb 16, 2025

Feb 16, 2025

Travere therapeutics director Roy Baynes sells $220,000 in stock - MSN

Feb 16, 2025

Feb 15, 2025

Sandra Calvin Sells 54,244 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock - MarketBeat

Feb 15, 2025

Feb 15, 2025

William E. Rote Sells 5,200 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock - MarketBeat

Feb 15, 2025

Feb 15, 2025

Eric M. Dube Sells 11,375 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock - MarketBeat

Feb 15, 2025

Feb 15, 2025

Scotiabank Issues Positive Forecast for Travere Therapeutics (NASDAQ:TVTX) Stock Price - MarketBeat

Feb 15, 2025

Feb 15, 2025

Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $45.00 at Canaccord Genuity Group - MarketBeat

Feb 15, 2025

Feb 15, 2025

Travere Therapeutics, Inc. (NASDAQ:TVTX) Director Sells $220,000.00 in Stock - MarketBeat

Feb 15, 2025

Feb 14, 2025

Travere therapeutics officer sells shares worth over $1.35 million - MSN

Feb 14, 2025

Feb 14, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Travere Therapeutics, Inc. (TVTX) Stockholders to Inquire about Securities Investigation - ACCESS Newswire

Feb 14, 2025

Feb 14, 2025

Travere Therapeutics (TVTX): Among The Small–Cap Stocks Insiders Are Selling Recently - Insider Monkey

Feb 14, 2025

Feb 14, 2025

10 Small–Cap Stocks Insiders Are Selling Recently - Insider Monkey

Feb 14, 2025

Feb 14, 2025

Travere Therapeutics price target raised to $47 from $45 at Guggenheim - TipRanks

Feb 14, 2025

Feb 14, 2025

Industry Analysts Just Made A Substantial Upgrade To Their Travere Therapeutics, Inc. (NASDAQ:TVTX) Revenue Forecasts - Simply Wall St

Feb 14, 2025

Feb 14, 2025

Travere Therapeutics (NASDAQ:TVTX) Sets New 1-Year HighTime to Buy? - MarketBeat

Feb 14, 2025

Feb 13, 2025

Canaccord raises Travere Therapeutics target to $45; Keeps Buy - MSN

Feb 13, 2025

Feb 13, 2025

Travere therapeutics SVP Elizabeth Reed sells $188,240 in stock By Investing.com - Investing.com Australia

Feb 13, 2025

Feb 13, 2025

Earnings Alert: Travere Therapeutics Sets Critical Q4 & FY24 Results RevealKey Details Inside - StockTitan

Feb 13, 2025

Feb 13, 2025

Travere Therapeutics Sparks Retail Frenzy As Stock Hits Over 2-Year High On FDA Approval Plan For Kidney-Disease Drug - MSN

Feb 13, 2025

Feb 13, 2025

Travere therapeutics CCO Heerma sells shares worth $137,275 - MSN

Feb 13, 2025

Feb 13, 2025

Travere Therapeutics price target raised to $32 from $27 at Scotiabank - Yahoo Finance

Feb 13, 2025

Feb 13, 2025

Travere therapeutics officer sells shares worth over $1.35 million By Investing.com - Investing.com South Africa

Feb 13, 2025

Feb 13, 2025

Travere therapeutics CEO Eric M. Dube sells $273,455 in stock - MSN

Feb 13, 2025

Feb 13, 2025

Travere therapeutics CCO Heerma sells shares worth $137,275 By Investing.com - Investing.com Nigeria

Feb 13, 2025

Feb 13, 2025

Travere therapeutics executive sells shares worth $122,356 By Investing.com - Investing.com South Africa

Feb 13, 2025